Sugi Predict

Sugi Predict / Targets / TPX2

TPX2

Targeting protein for Xklp2 · Q9ULW0 · TPX2 on Sugi Atlas →

6,317 patent compounds predicted against TPX2, 3,846 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL581172 SCHEMBL581172 0.60 9/20
SCHEMBL580404 SCHEMBL580404 0.59 9/20
SCHEMBL580688 SCHEMBL580688 0.80 8/20
SCHEMBL580575 SCHEMBL580575 0.68 8/20
SCHEMBL580462 SCHEMBL580462 0.66 8/20
SCHEMBL580890 SCHEMBL580890 0.66 8/20
SCHEMBL580672 SCHEMBL580672 0.65 8/20
SCHEMBL580935 SCHEMBL580935 0.65 8/20
SCHEMBL580848 SCHEMBL580848 0.64 8/20
SCHEMBL580846 SCHEMBL580846 0.64 8/20
SCHEMBL581074 SCHEMBL581074 0.64 8/20
SCHEMBL580434 SCHEMBL580434 0.63 8/20
SCHEMBL580992 SCHEMBL580992 0.63 8/20
SCHEMBL580268 SCHEMBL580268 0.62 8/20
SCHEMBL581544 SCHEMBL581544 0.61 8/20
SCHEMBL581609 SCHEMBL581609 0.61 8/20
SCHEMBL580947 SCHEMBL580947 0.61 8/20
SCHEMBL581058 SCHEMBL581058 0.61 8/20
SCHEMBL580303 SCHEMBL580303 0.61 8/20
SCHEMBL580513 SCHEMBL580513 0.60 8/20

Clinical trials — most relevant to TPX2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes PHASE4COMPLETED
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH PHASE3COMPLETED
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
Turner Syndrome: Genotype and Phenotype nanCOMPLETED
X-Chromosome Inactivation Status and Premature Ovarian Failure nanCOMPLETED
Molecular Associations With Reproductive Failure nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Screening for Hepatitis Virus B Protein X (HBx) in Colitis-associated Cancer (CAC) nanNOT_YET_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Molecular Markes of Fibrosis of Endometriosis and Their Use in Predicting Disease Severity nanRECRUITING
Study of the Sex Differences in Inflammatory Diseases in Children nanUNKNOWN
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Use of miRNAs in Growth Hormone Deficiency (GHD) nanUNKNOWN
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Gene x Behavior Interaction in the Look AHEAD Study nanCOMPLETED
Using QPOP to Predict Treatment for Sarcomas and Melanomas nanRECRUITING
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions nanRECRUITING
Identifying New Therapeutic Targets for Lupus Treatment nanCOMPLETED
The Etiology and Progression of Brain Tumors nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TPX2 binder may also engage these)

ProteinNameSimilarity
Q5RAF2 — 1.000 Q5RAF2 →
A6H6Z7 — 1.000 A6H6Z7 →
Q6DDV8 — 1.000 Q6DDV8 →
A2APB8 — 1.000 A2APB8 →
A4IH24 — 0.995 A4IH24 →
Q6NUF4 — 0.995 Q6NUF4 →
E2RYF8 — 0.987 E2RYF8 →
Q3B820 — 0.987 Q3B820 →
F4I2H7 — 0.985 F4I2H7 →
Q6AY14 — 0.985 Q6AY14 →
Q66KE9 — 0.983 Q66KE9 →
Q84ZT9 — 0.982 Q84ZT9 →
Q8CB59 — 0.982 Q8CB59 →
B0BM24 — 0.981 B0BM24 →
Q9WU62 — 0.980 Q9WU62 →
P13505 — 0.979 P13505 →
O95990 — 0.978 O95990 →
A5A6J4 — 0.978 A5A6J4 →
Q8IWZ8 — 0.977 Q8IWZ8 →
Q28E45 — 0.977 Q28E45 →
Q5EAW4 — 0.977 Q5EAW4 →
Q0IHP2 — 0.977 Q0IHP2 →
Q9ERH4 — 0.977 Q9ERH4 →
Q5NVK0 — 0.975 Q5NVK0 →
Q9NQW6 — 0.975 Q9NQW6 →
Q9Z1S0 — 0.975 Q9Z1S0 →
Q5TID7 — 0.975 Q5TID7 →
Q7T0S7 — 0.975 Q7T0S7 →
Q6DD45 — 0.975 Q6DD45 →
E7F7X0 — 0.975 E7F7X0 →